Ventilation Acquired Pneumonia
Conditions
Keywords
ventilator-associated pneumonia, pandrug-resistant, extensively drug-resistant
Brief summary
The goal of this clinical trial is to determine the most effective empirical therapy of antibiotics for better ventilator-associated pneumonia control. The main question it aims to answer is: • Which is better for clinical response single or combination empiric antibiotic therapies ?
Interventions
COMBINATION_PRODUCTextended meropenem infusion in combination with other options such as Polymyxin, Tigecycline, Ertapenem, or Amikacin.
In the case of XDR or PDR Pseudomonas spp. or Acinetobacter spp. isolation from the patient's specimen, treatment was adjusted to extended meropenem infusion in combination with other options such as Polymyxin, Tigecycline, Ertapenem, or Amikacin in group (A) of patients.
COMBINATION_PRODUCTtwo β-lactam antibiotics plus a single non-β-lactam antibiotic
In the case of XDR or PDR Pseudomonas spp. or Acinetobacter spp. isolation from the patient's specimen, treatment was adjusted to include two β-lactam antibiotics plus a single non-β-lactam antibiotic, or a combination of double β-lactam antibiotics, with the aim of avoiding aggressive and toxic antibiotics in group (B) of patients
OTHERControl group received standard therapy
Treatment was adjusted to the second-line empirical antibiotic according to the hospital's local policy.
Sponsors
Cairo University
Beni-Suef University
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
1 Months to 12 Years
Healthy volunteers
No
Inclusion criteria
-Patients ranging from one month to twelve years old, who had been undergoing mechanical ventilation for over 48 hours and were diagnosed with Ventillator Associated Pneumonia. 2.1.3.
Exclusion criteria
* Patients with pneumonia prior to mechanical ventilation initiation. * Patients who had been intubated for more than 24 hours before admission to the PICU, or those transferred from other PICUs and were already receiving antibiotic therapy.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Antimicrobial susceptibility | 7 days | Antimicrobial susceptibility was assessed through Kirby-Bauer's disc diffusion method (DD), Minimal Inhibitory Concentration (MIC) using the automated VITEK 2 compact system (bioMérieux, France), and the Ameri-Ziaei Double Antibiotic Synergism Test (AZDAST). Interpretation of DD and MIC results followed CLSI guidelines. |
Countries
Egypt
Outcome results
None listed